Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
about
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasNew insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphomaCAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in LymphomaA phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.Integrative systems medicine approaches to identify molecular targets in lymphoid malignanciesFollow-up care for survivors of lymphoma who have received curative-intent treatmentBeyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cellsThe significance of FOXP1 in diffuse large B-cell lymphoma.Management of Incidental Findings in the Era of Next-generation SequencinghemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision MedicineLow dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.Paediatric non-Hodgkin lymphoma - perspectives in translational biologyDe novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma.N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway.Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells.Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma.Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort StudyWhole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09).Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.IX. Is it only about MYC? How to approach the diagnosis of diffuse large B-cell lymphomas.Human leukocyte antigens and genetic susceptibility to lymphoma.The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW.Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.B-cell receptor pathway modulators in NHL.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies.Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
P2860
Q26749139-0A207750-F8AC-4E31-A9D6-BD408DBF6470Q26765273-5EFFE088-6699-422A-A4EB-8E5ED964AADFQ26800814-9CB337DB-3D74-4035-BBCF-268668DD508DQ27320446-E7A80004-5602-4331-8434-3496AA4AAA41Q28067817-032E8D55-87B5-4AEB-BBCB-C0151267DAB1Q28077086-440788C2-2349-489B-B6F5-0D9B0453DDCAQ30275206-F2FFCAE7-76FB-4BAE-8648-1DC49FECE2E9Q30967984-1CE1B1FD-DAA7-4D2F-8375-DCF0EE7E050BQ33823801-3235A81E-CD06-4BCB-B76E-06DBE53F96AAQ34047455-46FEEB79-A7F5-47AD-AF31-9327D013CAA3Q35697689-93BA1ACE-BF3F-44A3-9A29-140535BF2733Q36152713-472A1AFB-109D-4A45-9B11-0EC97524529EQ36725307-773920F1-7A56-4BE0-81BF-29AA1A008E31Q36889143-5FA54283-A3E7-4539-8301-05BDA3DDC0F0Q36928813-E6C90171-1E6D-43A5-A5F2-C3856D71EFBFQ36996542-B00010CF-F28B-4FBC-9A38-48AD66442FA6Q37216467-C998D31A-2F19-4F7A-BEEE-67FA43EAD473Q37229779-24CED344-4434-40B8-BE23-ECFE7A55823FQ37373066-45038AC0-8957-4AEA-811C-29947D5C8150Q37424884-9B391EF2-7998-4546-BF2E-BD155AA7D773Q37620821-F469099E-48AE-484C-A38D-D567BC0947C9Q37624237-5C5CB28C-F3F1-4E6B-B52B-9C5F91614B53Q37699251-CDA74344-72D1-4472-B374-A3DA07883E95Q37706621-8DA68C1C-4A53-4E33-954B-3191216E2630Q37708919-EBC6AC09-069F-4119-BDA0-CE7FF72A6D24Q38523996-B65F8112-8133-4A8C-AD59-866D8BAEBC87Q38550267-028C9BBF-A044-4587-B761-DBA5D8D6E5A5Q38565503-5067BD4D-C1F9-42DF-BF88-26D2FE24B844Q38568358-B086E0DB-9532-4E11-869F-089394C865D8Q38601661-D1D30EEC-6167-4569-9641-18A96843338AQ38642477-0EB39CF9-D4D1-4562-9C81-C03EEDA97F5CQ38659428-9D5454CF-37C6-44FB-B472-E7D2579FE9DAQ38691282-38483F3C-CF5C-49E9-A8E2-E117CC64A79FQ38727095-94F93839-A1B9-444C-9B27-7AEC3D8F4E63Q38738390-1E62A250-0730-487F-A4B3-48CA2208F0A8Q38757931-032EF61C-EC8B-416D-B2B0-3D60F296ABD8Q38787141-EE4713BC-54B5-4B65-9878-6CFAA61BDA3DQ38812362-A928E2C6-CA49-47CB-B5A4-53ED6AE93F39Q38831146-CEB372E6-4377-4153-9BD7-CFE2B7ECAA28Q38857428-712F3832-84CC-4A33-B353-87A80E0D91CB
P2860
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Diffuse large B-cell lymphoma: ...... al and biologic heterogeneity.
@en
type
label
Diffuse large B-cell lymphoma: ...... al and biologic heterogeneity.
@en
prefLabel
Diffuse large B-cell lymphoma: ...... al and biologic heterogeneity.
@en
P1433
P1476
Diffuse large B-cell lymphoma: ...... al and biologic heterogeneity.
@en
P2093
Laurie H Sehn
P356
10.1182/BLOOD-2014-05-577189
P407
P577
2014-12-11T00:00:00Z